share_log

Concerns Surrounding Hangzhou Coco Healthcare ProductsLtd's (SZSE:301009) Performance

Concerns Surrounding Hangzhou Coco Healthcare ProductsLtd's (SZSE:301009) Performance

杭州可可保健品股份有限公司(SZSE:301009)業績表現存在的問題
Simply Wall St ·  11/02 20:47

Hangzhou Coco Healthcare Products Co.,Ltd.'s (SZSE:301009) robust recent earnings didn't do much to move the stock. We believe that shareholders have noticed some concerning factors beyond the statutory profit numbers.

杭州可可保健製品有限公司(SZSE:301009)最近的強勁收益並沒有對股價產生太大影響。我們認爲股東們注意到了一些超出法定利潤數字的令人擔憂的因素。

big
SZSE:301009 Earnings and Revenue History November 3rd 2024
SZSE:301009 盈利和營業收入歷史數據 2024年11月3日

How Do Unusual Items Influence Profit?

非常規項目如何影響利潤?

Importantly, our data indicates that Hangzhou Coco Healthcare ProductsLtd's profit received a boost of CN¥1.9m in unusual items, over the last year. While we like to see profit increases, we tend to be a little more cautious when unusual items have made a big contribution. When we crunched the numbers on thousands of publicly listed companies, we found that a boost from unusual items in a given year is often not repeated the next year. Which is hardly surprising, given the name. Hangzhou Coco Healthcare ProductsLtd had a rather significant contribution from unusual items relative to its profit to September 2024. All else being equal, this would likely have the effect of making the statutory profit a poor guide to underlying earnings power.

重要的是,我們的數據顯示,杭州可可保健製品有限公司的利潤在過去一年中由於不尋常項目的增加而獲得了190萬元人民幣的提升。雖然我們喜歡看到利潤增長,但當不尋常項目做出重大貢獻時,我們往往會更加謹慎。當我們對成千上萬家上市公司的數據進行分析時,我們發現某一年來自不尋常項目的提升在下一年通常不會重複。這並不奇怪,考慮到其名稱。與2024年9月相比,杭州可可保健製品有限公司的不尋常項目對其利潤貢獻相當顯著。其他條件相同的情況下,這可能會導致法定利潤不再是基礎盈利能力的有效指引。

That might leave you wondering what analysts are forecasting in terms of future profitability. Luckily, you can click here to see an interactive graph depicting future profitability, based on their estimates.

這可能會讓您想知道分析師對未來盈利能力的預測。幸運的是,您可以單擊此處查看基於其估計的未來盈利能力的互動圖表。

Our Take On Hangzhou Coco Healthcare ProductsLtd's Profit Performance

我們對杭州可可健康保健產品有限公司的利潤表現看法

As previously mentioned, Hangzhou Coco Healthcare ProductsLtd's large boost from unusual items won't be there indefinitely, so its statutory earnings are probably a poor guide to its underlying profitability. As a result, we think it may well be the case that Hangzhou Coco Healthcare ProductsLtd's underlying earnings power is lower than its statutory profit. On the bright side, the company showed enough improvement to book a profit this year, after losing money last year. The goal of this article has been to assess how well we can rely on the statutory earnings to reflect the company's potential, but there is plenty more to consider. Keep in mind, when it comes to analysing a stock it's worth noting the risks involved. Case in point: We've spotted 1 warning sign for Hangzhou Coco Healthcare ProductsLtd you should be aware of.

正如先前提到的,杭州可可保健產品有限公司由於飛凡項目的大幅提升,在這一特殊項目的幫助下,公司的法定收入可能不會無限期存在,因此,其財務報表收益可能不是判斷其潛在盈利能力的良好指標。因此,我們認爲杭州可可保健產品有限公司的潛在收益能力可能低於其法定利潤。好消息是,公司今年實現了盈利,而去年則虧損。本文的目的是評估我們能否依靠財務報表收益來反映公司的潛在,但還有許多因素需考慮。請牢記,在分析股票時,注意其中涉及的風險是值得的。例如,我們發現了杭州可可保健產品有限公司的一個警示信號,您應該注意。

This note has only looked at a single factor that sheds light on the nature of Hangzhou Coco Healthcare ProductsLtd's profit. But there is always more to discover if you are capable of focussing your mind on minutiae. For example, many people consider a high return on equity as an indication of favorable business economics, while others like to 'follow the money' and search out stocks that insiders are buying. While it might take a little research on your behalf, you may find this free collection of companies boasting high return on equity, or this list of stocks with significant insider holdings to be useful.

這篇筆記只研究了一個揭示杭州可可保健產品有限公司利潤性質的因素。但如果您能將注意力集中在細枝末節上,則還有更多發現。例如,許多人認爲高淨資產收益率是有利的商業經濟指標,而其他人喜歡「追隨資金」並尋找內部人員正在買入的股票。儘管這可能需要您進行一些研究,但您可能會發現這些擁有高淨資產收益率的公司的免費合集,或者具有顯著內部持股的股票列表非常有用。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂嗎?請直接與我們聯繫。或者,發送電子郵件至editorial-team @ simplywallst.com。
Simply Wall St的這篇文章是一般性質的。我們僅基於歷史數據和分析師預測提供評論,使用公正的方法,我們的文章並非意在提供財務建議。這並不構成買入或賣出任何股票的建議,並且不考慮您的目標或財務狀況。我們旨在爲您帶來基於基礎數據驅動的長期聚焦分析。請注意,我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St對提及的任何股票都沒有持倉。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論